This is a paid press release. Contact the press release distributor directly with any inquiries.
Orion Corporation’s <a href="https://bitcomme.com/kingsway-financial-services-q2-earnings-call-highlights/” title=”Kingsway Financial Services Q2 Earnings Call Highlights”>financial reporting and Annual General Meeting in 2027
- 271560.KS
- ORNAV.HE
- ORNBV.HE
ORION CORPORATION
STOCK EXCHANGE RELEASE – FINANCIAL CALENDAR
17 JULY 2026 at 10.30 EEST
Orion Corporation will publish its Financial Statement Release 2026 on Wednesday, 17 February 2027. The Financial Statements and the Report by the Board of Directors for 2026 will be published at the latest in week 9/2027.
The publication dates of the Interim Reports and the Half-Year Financial Report in 2027 are as follows:
|
Interim Report January-March 2027 |
|
|
Half-Year Financial Report January-June 2027 |
|
|
Interim Report January-September 2027 |
Orion’s financial reports will be published at approximately 8.30 am Finnish time.
The Annual General Meeting is planned to be held on Tuesday, 23 March 2027.
Financial reports and related presentation material are available at http://www.orionpharma.com/investors promptly after the publishing. The website also provides a possibility to register on Orion’s mailing lists for releases.
|
Liisa Hurme President and CEO |
Mikko Kemppainen General Counsel |
Contact person:
Tuukka Hirvonen, Head of Investor Relations
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orionpharma.com
Orion Pharma is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals as well as active pharmaceutical ingredients, combining our trusted expertise with continuous innovation. We have an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by us are used to treat cancer, respiratory diseases and neurological diseases, among others. In 2025 our net sales amounted to EUR 1,890 million, and we employ about 4,000 professionals worldwide, dedicated to building well-being.
